BDPT BioAdaptives Inc

BioAdaptives, Inc.’s Board of Directors Approves a One-for-One Stock Dividend

BioAdaptives, Inc.’s Board of Directors Approves a One-for-One Stock Dividend

LAS VEGAS, Dec. 03, 2024 (GLOBE NEWSWIRE) -- via IBN – (OTC: BDPT) Board of Directors has approved a dividend to all common stockholders. They will receive matching shares for all of the shares they own on the Record Date.

CEO James Keener stated, “This dividend is designed to acknowledge your steadfast belief in our vision and to reward you for standing by us as valued stakeholders.”

Key Details:

  • Dividend Structure: One additional share of common stock for each share owned as of the record date.
  • Record Date: Projected for the second week of January 2025
  • Payment Date: Within 15 days from the Record Date

Keener added, “This special dividend aligns with our dedication to enhancing shareholder value while reinforcing our focus on long-term growth and success. The additional shares you will receive signify our shared optimism for the future and our determination to deliver results that benefit all stakeholders.”

About BioAdaptives, Inc.

BioAdaptives, Inc. (OTC: BDPT) is a leader in the nutritional products industry, committed to delivering innovative solutions that enhance quality of life, anti-aging, cell repair, and well-being. With a deep focus on research, customer insights, and sustainable practices, BioAdaptives Inc. redefines what customers can expect from nutritional products. For more information, visit .

Forward-Looking Statements:

This press release contains forward-looking statements, including those related to the anticipated performance and success of the new product line. These statements are subject to risks and uncertainties that could materially cause actual results to differ. Please refer to our filings with the Securities and Exchange Commission for more information on potential risks.

Contact:

Emily Harrison

Investor Relations

BioAdaptives, Inc.

(702) 659-8829

Wire Service Contact:

IBN

Los Angeles, California



310.299.1717 Office



EN
03/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioAdaptives Inc

 PRESS RELEASE

BioAdaptives® Announces Commercial Launch of MyndMed™ Following Succes...

BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing Comprehensive cognitive-support formula now available online; company scaling production for anticipated Q4 demand LAS VEGAS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- via IBN -- (OTC: BDPT) today announced the commercial availability of MyndMed™, a next-generation cognitive-support dietary supplement formulated to support memory, focus, mental clarity, and overall brain performance. Following rigorous testing with overwhelmingly positive results, the company is expanding distribution and scaling inventory...

 PRESS RELEASE

BioAdaptives’ MyndMed™ Receives Full Clearance from TruShield™, Meetin...

BioAdaptives’ MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety Unique nootropic formula blends botanical extracts, amino acids and neuro-support nutrients to support balance, energy and resilience in athletes LAS VEGAS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- via IBN – (OTCMKTS: BDPT), a leader in natural health and performance supplements, today announced that its flagship nootropic formula, MyndMed™, has been officially certified clean by TruShield™ Laboratory Services, a trusted provider of sports supplement testing specializing in World ...

 PRESS RELEASE

BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge ...

BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience NeuroRush™ delivers a unique blend of adaptogens and nootropic herbs designed to enhance cognitive performance, stress response and long-term brain health, without dependency or burnout. LAS VEGAS, July 16, 2025 (GLOBE NEWSWIRE) -- (OTC: BDPT), an innovator in evidence-based wellness solutions, today announced the upcoming national release of NeuroRush™, a next-generation nootropic designed to support sustained cognitive performance, mental clarity, and ...

 PRESS RELEASE

BioAdaptives Announces National Launch of Pawpa™ Regen

BioAdaptives Announces National Launch of Pawpa™ Regen Revolutionary Canine Supplement Promotes Regenerative Healing Through Stem Cell Activation LAS VEGAS , June 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- (OTC Pink: BDPT), an innovator in nutraceutical and wellness science, today announces the upcoming national release of , a proprietary canine supplement that supports natural stem cell activation and regenerative healing in aging dogs. After a successful limited market release earlier this year, Pawpa™ Regen officially launches nationwide at the end of July 2025. This breakthrough form...

 PRESS RELEASE

BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for...

BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR® Scale Improvements Regen Dog Chews are crafted to the highest quality standards, recommended by veterinarians and proven safe with no adverse effects reported in clinical trials LAS VEGAS, May 28, 2025 (GLOBE NEWSWIRE) -- via IBN -- . (OTC: BDPT), through its pets division PawPa™, a leader in premium pet wellness, proudly announces the remarkable stem cell benefits of its flagship product, Regen Dog Chews, validated through rigorous clinical testing and the innovative APBAR® r...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch